{
    "root": "8ff13251-1ffd-4a33-8037-7dc7bfc1f2a2",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Heparin Sodium",
    "value": "20250505",
    "ingredients": [
        {
            "name": "HEPARIN SODIUM",
            "code": "ZZ45AB24CA",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_230519"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        },
        {
            "name": "BENZYL ALCOHOL",
            "code": "LKG8494WBH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17987"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "NITROGEN",
            "code": "N762921K75",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09152"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        }
    ],
    "indications": {
        "text": "heparin sodium injection indicated : \u2022prophylaxis treatment venous thrombosis pulmonary embolism \u2022prevention postoperative deep venous thrombosis pulmonary embolism patients undergoing major abdominothoracic surgery , reasons , risk developing thromboembolic disease \u2022atrial fibrillation embolization \u2022treatment acute chronic consumptive coagulopathies ( disseminated intravascular coagulation ) \u2022prevention clotting arterial cardiac surgery \u2022prophylaxis treatment peripheral arterial embolism \u2022anticoagulant blood transfusions , extracorporeal circulation , dialysis procedures",
        "doid_entities": [
            {
                "text": "thrombosis (DOID:0060903)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060903"
            },
            {
                "text": "pulmonary embolism (DOID:9477)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9477"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "disseminated intravascular coagulation (DOID:11247)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11247"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "recommended adult dosages : \u2022 therapeutic anticoagulant effect full-dose heparin sodium injection \u2020 ( 2.3 ) \u2020 based 150 lb ( 68 kg ) patient . adjust dose based laboratory monitoring . deep subcutaneous ( intrafat ) injection different site injection initial dose 5,000 units intravenous injection , followed 10,000 20,000 units concentrated solution , subcutaneously every 8 hours every 12 hours 8,000 10,000 units concentrated solution 15,000 20,000 units concentrated solution intermittent intravenous injection initial dose 10,000 units , either undiluted 50 100 ml 0.9 % sodium chloride injection , usp every 4 6 hours 5,000 10,000 units , either undiluted 50 100 ml 0.9 % sodium chloride injection , usp intravenous infusion initial dose 5,000 units intravenous injection continuous 20,000 40,000 units/24 hours 1,000 ml 0.9 % sodium chloride injection , usp ( compatible solution ) infusion",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "heparin sodium injection , usp preserved benzyl alcohol available follows : ndc strength ( concentration ) vial fill volume vial type package factor 55154-2827-5 5,000 usp units per ml 1 ml 1 ml vial overbagged 5 x 1 ml vials bag , ndc 55154-2827-5 warning : unit dose package child resistant intended institutional . keep drugs reach children . sterile , nonpyrogenic . container closure made natural rubber latex . storage conditions store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) . [ usp controlled room temperature . ]",
    "adverseReactions": "heparin sodium contraindicated patients following conditions : \u2022history heparin-induced thrombocytopenia heparin-induced thrombocytopenia thrombosis [ ( 5.3 ) ] \u2022known hypersensitivity heparin pork products ( e.g . , anaphylactoid ) [ ( 6.1 ) ] \u2022in suitable blood coagulation tests , e.g . , whole blood clotting time , partial thromboplastin time , etc . , performed appropriate intervals ( contraindication refers full-dose heparin ; usually need monitor coagulation parameters patients receiving low-dose heparin ) \u2022an uncontrolled active bleeding state [ ( 5.4 ) ] , except due disseminated intravascular coagulation",
    "indications_original": "Heparin Sodium Injection is indicated for: \n                  \n                     \n                        \u2022Prophylaxis and treatment of venous thrombosis and pulmonary embolism \n                     \n                        \u2022Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease \n                     \n                        \u2022Atrial fibrillation with embolization \n                     \n                        \u2022Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation) \n                     \n                        \u2022Prevention of clotting in arterial and cardiac surgery \n                     \n                        \u2022Prophylaxis and treatment of peripheral arterial embolism \n                     \n                        \u2022Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures",
    "contraindications_original": "Recommended Adult Dosages: \u2022 Therapeutic Anticoagulant Effect with Full-Dose Heparin Sodium Injection \u2020 ( 2.3 ) \u2020 Based on 150 lb (68 kg) patient. Adjust dose based on laboratory monitoring. Deep Subcutaneous (Intrafat) Injection Use a different site for each injection Initial Dose 5,000 units by intravenous injection, followed by 10,000 to 20,000 units of a concentrated solution, subcutaneously Every 8 hours or Every 12 hours 8,000 to 10,000 units of a concentrated solution 15,000 to 20,000 units of a concentrated solution Intermittent Intravenous Injection Initial dose 10,000 units, either undiluted or in 50 to 100 mL of 0.9% Sodium Chloride Injection, USP Every 4 to 6 hours 5,000 to 10,000 units, either undiluted or in 50 to 100 mL of 0.9% Sodium Chloride Injection, USP Intravenous Infusion Initial dose 5,000 units by intravenous injection Continuous 20,000 to 40,000 units/24 hours in 1,000 mL of 0.9% Sodium Chloride Injection, USP (or in any compatible solution) for infusion",
    "warningsAndPrecautions_original": "Heparin Sodium Injection, USP preserved with benzyl alcohol is available as follows: \n                  \n                     \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 NDC\n                              \n                           \n                           \n                              \n                                 Strength\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \n                                 \n                                 (Concentration)\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \n                              \n                           \n                           \n                              \n                                 Vial Fill Volume\n                              \n                           \n                           \n                              \n                                 Vial Type\n                              \n                           \n                           \n                              \n                                 Package Factor\n                              \n                           \n                        \n                        \n                           \n                              55154-2827-5\n                           \n                           \n                              5,000 USP units per mL \n                           \n                           \n                              1 mL \n                           \n                           \n                              1 mL Vial \n                           \n                           \n                              Overbagged with 5 x 1 mL vials in each bag,\u00a0NDC 55154-2827-5\n                           \n                        \n                     \n                  \n                  WARNING: This Unit Dose package is not child resistant and is Intended for Institutional Use Only. Keep this and all drugs out of the reach of children.\n                  \n                     Sterile, Nonpyrogenic.\n                     \n                     The container closure is not made with natural rubber latex.\n                  \n                  \n                     Storage Conditions\n                     \n                     Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.]",
    "adverseReactions_original": "The use of heparin sodium is contraindicated in patients with the following conditions: \n                  \n                     \n                        \u2022History of heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis [see Warnings and Precautions (5.3)]\n                     \n                     \n                        \u2022Known hypersensitivity to heparin or pork products (e.g., anaphylactoid reactions) [see Adverse Reactions (6.1)]\n                     \n                     \n                        \u2022In whom suitable blood coagulation tests, e.g., the whole blood clotting time, partial thromboplastin time, etc., cannot be performed at appropriate intervals (this contraindication refers to full-dose heparin; there is usually no need to monitor coagulation parameters in patients receiving low-dose heparin) \n                     \n                        \u2022An uncontrolled active bleeding state [see Warnings and Precautions (5.4)], except when this is due to disseminated intravascular coagulation",
    "drug": [
        {
            "name": "Heparin Sodium",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_230519"
        }
    ]
}